86953-81-3

Usage

Uses

Used in Pharmaceutical Industry:
N-BOC-2-HYDROXYPIPERIDINE is used as a building block in organic synthesis for the development of various drugs and medicinal compounds. Its Boc protecting group allows for easier handling and manipulation in reactions, making it a valuable intermediate in the production of pharmaceutical products.

Upstream product

• 94136-78-4 5-<(tert-butoxycarbonyl)amino>pentanal 
• 586-96-9 Nitrosobenzene 
• 85908-96-9 2-oxopiperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 118811-07-7 tert-butyl 4-(tosyloxy)piperidin-1-carboxylate 
• 1067651-09-5 tert-butyl (S)-2-((6R,7aS)-6-((tert-butyldiphenylsilyl)oxy)-2-oxo-6,7-dihydrobenzofuran-7a(2H)-yl)piperidine-1-carboxylate 
• 1067651-14-2 (2R,6S,7aR)-tert-butyl 2-(6-(tert-butyldiphenylsilanyloxy)-2-oxo-6,7-dihydro-2H-benzofuran-7a-yl)piperidine-1-carboxylate 
• 1067651-06-2 (2S,7aS,4'R,5'R)-tert-butyl 2-{4',5'-diphenyl-2-oxo-7,7a-dihydrospiro[benzofuran-6(2H),2'-[1,3]dioxolan]-7a(7H)-yl}piperidine-1-carboxylate 
• 195964-51-3 tert-butyl 2-methoxypiperidine-1-carboxylate 
• 1427072-49-8 (E)-N-tert-butoxycarbonyl-2-(3'-cyclohexylideneprop-1'-en-1'-yloxy)piperidine 
• 1427072-47-6 (Z)-N-tert-butoxycarbonyl-2-(4’-methoxy-6’-phenylhex-2’-en-1’-yloxy)piperidine 
• 1427072-58-9 (1E)-N-tert-butoxycarbonyl-2-(6′-phenylhexa-1′,3′-dien-1′-yloxy)piperidine 
• 1427072-59-0 (1E)-N-tert-butoxycarbonyl-2-(6′-phenylhexa-1′,3′-dien-1′-yloxy)piperidine 
• 1427072-60-3 (1Z)-N-tert-butoxycarbonyl-2-(6′-phenylhexa-1′,3′-dien-1′-yloxy)piperidine 
• 1427072-44-3 (Z)-N-tert-butoxycarbonyl-2-(3’-(1’’-methoxycyclohexyl)allyloxy)piperidine 
• 221664-11-5 (4S,9aS)-4-(3,4-dimethoxyphenyl)hexahydro-1H-quinolizin-2(6H)-one 
• 436145-75-4 (4R,9aS)-4-(3,4-dimethoxyphenyl)octahydro-2H-quinolizin-2-one 
• 1202039-12-0 (+)-(2R)-(2-oxopropyl)piperidine-1-carbamic acid tert-butylester 

Relevant academic research and scientific papers

Backbone-Modified C2-Symmetrical Chiral Bisphosphine TMS-QuinoxP*: Asymmetric Borylation of Racemic Allyl Electrophiles

A new C2-symmetrical P-chirogenic bisphosphine ligand with silyl substituents on the ligand backbone, (R,R)-5,8-TMS-QuinoxP*, has been developed. This ligand showed higher reactivity and enantioselectivity for the direct enantioconvergent borylation of cy

Synthesis of functionalised azepanes and piperidines from bicyclic halogenated aminocyclopropane derivatives

A series of 6,6-dihalo-2-azabicyclo[3.1.0]hexane and 7,7-dihalo-2-azabicyclo[4.1.0]heptane compounds were prepared by the reaction of dihalocarbene species with N-Boc-2,3-dihydro-1H-pyrroles or -1,2,3,4-tetrahydropyridines. Monochloro substrates were synthesised as well, using a chlorine-to-lithium exchange reaction. The behaviour of several aldehydes and ketones under reductive amination conditions with deprotected halogenated secondary cyclopropylamines was investigated, showing that this transformation typically triggers cyclopropane ring cleavage to give access to interesting nitrogen-containing ring-expanded products.

Hydrozirconation of four-, five-, six- and seven-membered N-alkoxycarbonyl lactams to lactamols

A general, practical, and efficient reduction of four-, five-, six- and, seven-membered N-alkoxycarbonyl lactams to the aldehyde oxidation state is reported. The reduction methodology involves the hydrozirconation reaction by Cp2Zr(H)Cl under m

Total synthesis of (±)- and (-)-actinophyllic acid

Development of efficient sequences for the total syntheses of (±)-actinophyllic acid (rac-1) and (-)-actinophyllic acid (1) are described. The central step in these syntheses is the aza-Cope/Mannich reaction, which constructs the previously unknown hexacyclic ring system of actinophyllic acid in one step from much simpler tetracyclic precursors. The tetracyclic hexahydro-1,5-methano-1H-azocino[4,3-b]indole ketone rac-37 is assembled from o-nitrophenylacetic acid in four steps, with oxidative cyclization of a dienolate derivative of tricyclic precursor rac-35 being the central step. In the first-generation synthesis, this intermediate is transformed in two steps to homoallyl amine rac-43, whose formaldiminium derivative undergoes efficient aza-Cope/Mannich reaction to give pentacyclic ketone rac-44. In four additional steps, this intermediate is advanced to (±)-actinophyllic acid. The synthesis is streamlined by elaborating ketone rac-37 to β-hydroxyester intermediate rac-53, which is directly transformed to (±)-actinophyllic acid upon exposure to HCl and paraformaldehyde. This concise second-generation total synthesis of (±)-actinophyllic acid is realized in 22% overall yield from commercially available di-tert-butyl malonate and o-nitrophenylacetic acid by a sequence that proceeds by way of only six isolated intermediates. The first enantioselective total synthesis of (-)-actinophyllic acid (1) is accomplished by this direct sequence from tricyclic keto malonate (S)-35. Catalytic enantioselective reduction of α,β-unsaturated ketone 66 is the key step in the preparation of intermediate (S)-35 from the commercially available Boc-amino acid 65. Discussed also is the possibility that the aza-Cope/Mannich reaction might be involved in the biosynthesis of (-)-actinophyllic acid.

Pyrrolopyrimidines as therapeutic agents

Chemical compounds having structural formula I and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatiod arthritis, disorders of the immune system, trasplant refections and imflammatory disorders.